Received: 04.01.2023 Accepted: 04.01.2023
Each year in early December, all hematology-related specialists look forward to the Annual Meeting of the American Society of Hematology (ASH). The 64th such event was held in New Orleans between 9 and 13 December 2022. The ASH Meeting is a very prestigious scientific meeting. All the most important hematological achievements are presented, and new trends are identified and announced at this gathering. Hematologists used to say that the status of hematology is always located either before or after the ASH Meeting. More than 20,000 attendees participated in the ASH Meeting in December 2022, which included more than 50 general or educational/scientific sessions, more than 50 satellite sessions, and almost 1,000 oral and 4,000 poster presentations selected from submitted abstracts.
The three General Lectures and Prizes were:
- Ham-Wasserman Lecture: Irene Roberts — Leukemogenesis in infants with trisomy 21;
- E. Donnall Thomas Lecture: Bruce R. Blazar — The long and winding road to clinically effective graft-versus-host disease (GvHD) therapeutics;
- Ernest Beutler Lecture: John Atkinson and Peter Hillmen — The complement system and medicine: the good, the bad, the future.
The highest-scoring Top 6 abstracts this year were the following:
- Dreyling et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network.
- Preston et al. An ancient transcriptional hub couples developmentally regulated gene expression with metabolism during erythropoiesis.
- Broome et al. Efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia: results of a phase III, multicenter, double-blinded, placebo-controlled, randomized clinical trial (ADVANCE IV).
- Stelljes et al. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: results from the randomized phase III ASAP trial.
- Grover et al. C1 inhibitor deficiency results in increased activation of coagulation and enhanced venous thrombosis.
- Reis et al. Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs).
At the 64th ASH Meeting, Polish scientists presented 22 posters, and coauthored 72 other studies, among them 25 oral (including abstracts #1 and #LBA-6) and 47 poster presentations. This is proof of high activity, at both national and international levels, which is continuously evolving [1–5].
Authors’ contributions
JS — sole author.
Conflict of interest
The author declares no conflict of interest.
Financial support
None.
Ethics
The work described in this article has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; EU Directive 2010/63/EU for animal experiments; Uniform requirements for manuscripts submitted to biomedical journals.
References
